Clinical Trial: NCT03967522
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Centre Leon Berard |
| Information Provided By: | Centre Leon Berard |
| Last Update Posted: | 2025-08-08 |
Study Overview
Brief Summary
This is a multicenter, open-label, exploratory, single-arm, prospective phase II study to assess the efficacy and safety profile of cabozantinib in patients with brain metastases from metastatic renal cell carcinoma (mRCC).
Official Title
CABRAMET: A Phase 2 Study of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases
Conditions
Metastatic Renal Cell Carcinoma
Intervention / Treatment
- Drug: Cabozantinib
Other Study ID Numbers
- CABRAMET (ET19-006)
Start Date (Actual)
2019-11-29
Primary Completion Date (Actual)
2024-10-22
Study Completion Date (Actual)
2024-11-01
Enrollment (Actual)
26
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Centre Leon Berard |
| Information Provided By: | Centre Leon Berard |
| Last Update Posted: | 2025-08-08 |
Study Overview
Brief Summary
This is a multicenter, open-label, exploratory, single-arm, prospective phase II study to assess the efficacy and safety profile of cabozantinib in patients with brain metastases from metastatic renal cell carcinoma (mRCC).
Official Title
CABRAMET: A Phase 2 Study of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases
Conditions
Metastatic Renal Cell Carcinoma
Intervention / Treatment
- Drug: Cabozantinib
Other Study ID Numbers
- CABRAMET (ET19-006)
Start Date (Actual)
2019-11-29
Primary Completion Date (Actual)
2024-10-22
Study Completion Date (Actual)
2024-11-01
Enrollment (Actual)
26
Study Type
Interventional
Phase
Phase 2